Zur klinischen Relevanz des Interleukin-6 und -18, 17β-Estradiol (E₂) und des Serumoxalats für das aktuelle biochemische Monitoring beim Mammakarzinom

Zusammenfassung

Fragestellung: Die Serumkonzentration verschiedener biochemischer Marker (Zytokine, NO, Oxalat, Steroide) wurde im Hinblick auf den klinischen Status der Erkrankung bewertet. Es wurde untersucht, ob unterschiedliche Konzentrationsverläufe während der verschiedenen Stadien des Mammakarzinoms vorlagen. Material und Methodik: Serumproben von 54 Patientinnen der Klinik für Frauenheilkunde und Geburtshilfe wurden untersucht. Die Oxalatkonzentration wurde mit einer Chemilumineszenz-(CL-)Methode bestimmt, IL-6 und -18 mit einem ELISA und E₂ mit einem kompetitiven Immunoassay unter Anwendung des direkten Chemilumineszenzverfahrens. Die statistische Auswertung erfolgte mit SPSS Version 17.0. Ergebnisse: Oxalat: tumorfrei (tf) (x¯ = 20,88 µmol/l)/1–2 Metastasenlokalisationen (ML) (x¯ = 20,16 µmol/l) p = 0,7; tf/3–4 ML (x¯ = 16,24 µmol/l) p = 0,033; 1–2 ML/3–4 ML p = 0,091. IL-6: tf (x¯ = 0,13 pg/ml)/1–2 ML (x¯ = 6,97 pg/ml) p < 0,0005; tf/3–4 ML (x¯ = 10,00 pg/ml) p < 0,0005; 1–2 ML/3–4 ML p = 0,045. IL-18: tf (x¯ = 297,45 pg/ml)/1–2 ML (x¯ = 295,19 pg/ml) p = 0,96; tf/3–4 ML (x¯ = 403,81 pg/ml) p = 0,20; 1–2 ML/3–4 ML p = 0,17. Estrogen: tf (x¯ = 53,86 pg/ml)/1–2 ML (x¯ = 31,54 pg/ml) p = 0,96; tf/3–4 ML (x¯ = 19,39 pg/ml) p = 0,20; 1–2 ML/3–4 ML p = 0,17. Schlussfolgerung: Oxalat, IL-6 und IL-18 erweisen sich als potenzielle Kandidaten für ein erweitertes biochemisches Monitoring des Mammakarzinoms.

Abstract

Purpose: To assess clinical manifestations of breast cancer we evaluated blood levels of oxalate, IL-6, IL-18 and estrogen. We aimed to reveal a correlation between blood levels and disease stage. Material and Methods: Blood samples were taken from 54 patients who presented to the Clinic for Gynecology and Obstetrics. Oxalate concentrations were measured by chemiluminescence, IL-6 and -18 levels with ELISA and estrogen by competitive immunoassay. Statistical analysis was done using SPSS version 17.0. Results: Oxalate: tf (x¯ = 20.88 µmol/l)/1–2 ML (x¯ = 20.16 µmol/l) p = 0.7; tf/3–4 ML (x¯ = 16.24 µmol/l) p = 0.033; 1–2 ML/3–4 ML p = 0.091. IL-6: tf (x¯ = 0.13 pg/ml)/1–2 ML (x¯ = 6.97 pg/ml) p < 0.0005; tf/3–4 ML (x¯ = 10.00 pg/ml) p < 0.0005; 1–2 ML/3–4 ML p = 0.045. IL-18: tf (x¯ = 297.45 pg/ml)/1–2 ML (x¯ = 295.19 pg/ml) p = 0.96; tf/3–4 ML (x¯ = 403.81 pg/ml) p = 0.20; 1–2 ML/3–4 ML p = 0.17. Estrogen: tf (x¯ = 53.86 pg/ml)/1–2 ML (x¯ = 31.54 pg/ml) p = 0.96; tf/3–4 ML (x¯ = 19.39 pg/ml) p = 0.20; 1–2 ML/3–4 ML p = 0.17. Conclusion: Oxalate, IL-6 and IL-18 are potential candidates for a better biochemical management of breast cancer.

Schlüsselwörter

Oxalat - Interleukin‐6 - Interleukin‐18 - Estradiol - Mammakarzinom

Key words

oxalate - interleukin 6 - interleukin 18 - estrogen - breast cancer

Literatur

• 1 Kamangar F, Dores G M, Anderson W F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.  J Clin Oncol. 2006;  24 2137-2150
• 2 Robert Koch Institute eds.. Cancer in Germany, 2003 – 2004. Incidence and Trends. 6th revised edition. Berlin: Robert Koch Institute; 2008
• 3 Catarino R, Ferreira M M, Rodrigues H et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer.  DNA Cell Biol. 2008;  27 415-421
• 4 Boros L G, Brackett D J, Harrigan G G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP).  Curr Cancer Drug Targets. 2003;  3 445-453
• 5 Albrecht S. Determination of serum oxalate using peroxyoxalate chemiluminescence of free oxalic acid.  J Biolumin Chemilumin. 1993;  8 21-24
• 6 Morgan M, Cooke M, Christopherson P et al. Calcium hydroxyapatite promotes mitogenesis and matrix metalloproteinase expression in human breast cancer cell lines.  Mol Carcinog. 2001;  32 111-117
• 7 Going J J, Anderson T J, Crocker P R et al. Weddellite calcification in the breast: eighteen cases with implications for breast cancer screening.  Histopathology. 1990;  16 119-124
• 8 Morgan M P, Cooke M M, McCarthy G M. Microcalcifications associated with breast cancer: an epiphenomenon of biologically significant feature of selected tumors?.  J Mammary Gland Biol Neoplasia. 2005;  10 181-187
• 9 Froung C, Meunier M, Guinebretiere J et al. Polyhedral microcalcifications at mammography: Histological correlation with calcium oxalate.  Radiology. 1993;  186 681-684
• 10 Boros L G, Brackett D J, Harrigan G G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP).  Curr Cancer Drug Targets. 2003;  3 445-453
• 11 Albrecht S. Oxalat – tatsächlich nur ein humanes Stoffwechsel-Endprodukt?.  Angew Chem. 1994;  106 1864-1865
• 12 Conze D, Weiss L, Regen P S et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.  Cancer Res. 2001;  61 8851-8858
• 13 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?.  Lancet. 2001;  357 539-545
• 14 Leek R, Harris A. Tumor-associated macrophages in breast cancer.  J Mammary Gland Biol. 2002;  7 177-189
• 15 Tumminello F M, Badalamenti G, Incorvaia L et al. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.  Med Oncol. 2009;  26 10-15
• 16 Rao V, Dyer C, Jameel J et al. Potential prognostic and therapeutic roles for cytokines in breast cancer.  Oncology Reports. 2006;  15 179-185
• 17 Zhang G J, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.  Anticancer Res. 1999;  19 1427-1432
• 18 Papanicolaou D A, Wilder R L, Manolagas S C et al. The pathophysiologic roles of interleukin-6 in human disease.  Ann Intern Med. 1998;  128 127-137
• 19 Vidal-Vanaclocha F, Mendoza L, Telleria N et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression.  Cancer Metastasis Rev. 2006;  25 417-434
• 20 Ambrosone C B, Ahn J, Singh K K et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer.  Cancer Res. 2005;  65 1105-1111
• 21 Günel N, Coşkun U, Sancak B et al. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients.  Cancer. 2002;  95 663-667
• 22 Golab J. Interleukin 18 – interferon gamma inducing factor – a novel player in tumour immunotherapy?.  Cytokine. 2000;  12 332-338
• 23 Okano F, Yamada K. Canine interleukin-18 induces apoptosis and enhances Fas ligand mrNa expression in a canine carcinoma cell line.  Anticancer Res. 2000;  20 3411-3415
• 24 Park C C, Morel J C, Amin M A et al. Evidence of IL-18 as a novel angiogenic mediator.  J Immunol. 2001;  167 1644-1653
• 25 Pasqualini J R, Cortes-Prieto J, Chetrite G et al. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma.  Int J Cancer. 1997;  70 639-643
• 26 Millington D S. Determination of hormonal steroid concentrations in biological extracts by high-resolution mass fragmentography.  J Steroid Biochem. 1975;  6 239-245
• 27 Key T, Appleby P, Barnes I et al. The endogenous hormones and breast cancer collaborative study. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective cohort studies.  J Natl Cancer Inst. 2002;  94 606-616
• 28 Key T J, Chen J, Wang D Y et al. Sex hormones in women in rural China and in Britain.  Br J Cancer. 1990;  62 631-636
• 29 Berrino F, Pasanisi P, Bellati C et al. Serum testosterone levels and breast cancer recurrence.  Int J Cancer. 2005;  113 499-502